Skip to main content
. Author manuscript; available in PMC: 2013 Aug 21.
Published in final edited form as: Circulation. 2012 Jul 11;126(8):963–974. doi: 10.1161/CIRCULATIONAHA.112.094722

Figure 4.

Figure 4

The effect of mineralocorticoid receptor antagonism on reversal or prevention of adverse cardiopulmonary hemodynamics in two models of experimental PAH. (a) In a reversal study, Sprague-Dawley rats were randomized to receive vehicle control (V) or spironolactone (SP) (25 mg/kg/d) 14 days following the administration of V or monocrotaline (MCT) (50 mg/kg), and cardiopulmonary hemodynamics were assessed by cardiac catheterization 10 days later. *p<0.02 vs. MCT, n=6 rats per condition; **p<0.04 vs. V, n=4 rats per condition. Data are presented as mean ± S.E. (b) In a prevention study, Sprague-Dawley rats were injected with SU-5416 and exposed to chronic hypoxia for 21 days. Immediately following exposure to hypoxia, rats were randomized to receive standard chow or eplerenone (0.6 gm/1 gm chow) until completion of the study. The effect of eplerenone on pulmonary artery systolic pressure (PASP) was assessed by cardiac catheterization (n=5 rats per condition). HR, heart rate; CI, cardiac index; LVEDP, left ventricular end-diastolic pressure; PVRi, pulmonary vascular resistance index; SVRi, systemic vascular resistance index.